CP and infection: In the intranasal vaccination using trivalent neuraminidase proteins formulated with LT-IIb-B<sub>5</sub> CP<sub>13-14</sub>, we demonstrated complete protection against heterologous H1N1 and H3N2 viral challenge infections.